Agios Pharmaceuticals | أصول متداولة



Current Assets تغيير تاريخ
AbbVie USD 25.58B 2.2B 2024-12
Agios Pharmaceuticals USD 965.6M 108.59M 2024-12
Alnylam Pharmaceuticals USD 3.3B 60.14M 2024-12
Amgen USD 29.03B 2.26B 2024-12
Arrowhead Research USD 570.54M 124.93M 2024-12
Astellas Pharma JPY 1.2T 904M 2024-12
AstraZeneca USD 25.83B 1.67B 2024-12
Bayer EUR 34.44B 1.31B 2024-12
Biogen USD 7.46B 626.3M 2024-12
BioMarin Pharmaceutical USD 3.23B 175.84M 2024-12
Bristol-Myers Squibb USD 29.78B 1.7B 2024-12
Daiichi Sankyo JPY 1.98T 79.43B 2024-12
Eli Lilly USD 32.74B 1.32B 2024-12
Exelixis USD 1.47B 82.14M 2025-01
Gilead Sciences USD 19.17B 4.39B 2024-12
GlaxoSmithKline GBP 17B 301M 2024-12
Incyte USD 3.24B 430.32M 2024-12
Ionis Pharmaceuticals USD 2.62B 93.56M 2024-12
Merck USD 38.78B 1.58B 2024-12
Moderna USD 8.1B 1.57B 2024-12
Novartis USD 29.7B 1.56B 2024-12
Novartis USD 29.7B 1.56B 2024-12
Pfizer USD 50.36B 7.14B 2024-12
Regeneron Pharmaceuticals USD 27.21B 7.88B 2024-12
Roche Holding CHF 40.04B 6.41B 2024-12
Sarepta Therapeutics USD 3.07B 388.09M 2024-12
Vertex Pharmaceuticals USD 9.6B 207.7M 2024-12



Agios Pharmaceuticals أصول متداولة - القيم الحالية، والبيانات التاريخية، والتنبؤات والإحصاءات والرسوم البيانية والتقويم الاقتصادي - Mar 2025.